CA2387545A1 - Methodes de traitement ou de prevention de lesions des cellules, des tissus et des organes utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1) d'origine humaine - Google Patents

Methodes de traitement ou de prevention de lesions des cellules, des tissus et des organes utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1) d'origine humaine Download PDF

Info

Publication number
CA2387545A1
CA2387545A1 CA002387545A CA2387545A CA2387545A1 CA 2387545 A1 CA2387545 A1 CA 2387545A1 CA 002387545 A CA002387545 A CA 002387545A CA 2387545 A CA2387545 A CA 2387545A CA 2387545 A1 CA2387545 A1 CA 2387545A1
Authority
CA
Canada
Prior art keywords
replaced
mpif
polypeptide
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002387545A
Other languages
English (en)
Inventor
Krzysztof J. Grzegorzewski
Craig A. Rosen
Vikram Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2387545A1 publication Critical patent/CA2387545A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des compositions et des méthodes thérapeutiques utilisant des molécules d'acides nucléiques isolées codant un polypeptide du facteur-1 inhibiteur des précurseurs myéloïdes (MPIF-1) d'origine humaine (précédemment appelé MIP-3 et chimiokine .beta.8 (CK.beta.8 ou ckb-8)), ainsi que ce polypeptide MPIF-1 lui-même, des vecteurs, des cellules hôtes et des méthodes de recombinaison destinées à la production de MPIF-1.
CA002387545A 1999-10-14 2000-10-13 Methodes de traitement ou de prevention de lesions des cellules, des tissus et des organes utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1) d'origine humaine Abandoned CA2387545A1 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US15936299P 1999-10-14 1999-10-14
US60/159,362 1999-10-14
US16405999P 1999-11-08 1999-11-08
US60/164,059 1999-11-08
US17206399P 1999-12-23 1999-12-23
US60/172,063 1999-12-23
US18904800P 2000-03-14 2000-03-14
US60/189,048 2000-03-14
US19914200P 2000-04-24 2000-04-24
US60/199,142 2000-04-24
US21145800P 2000-06-13 2000-06-13
US60/211,458 2000-06-13
US21265800P 2000-06-19 2000-06-19
US60/212,658 2000-06-19
PCT/US2000/028349 WO2001026676A1 (fr) 1999-10-14 2000-10-13 Methodes de traitement ou de prevention de lesions des cellules, des tissus et des organes utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1) d'origine humaine

Publications (1)

Publication Number Publication Date
CA2387545A1 true CA2387545A1 (fr) 2001-04-19

Family

ID=27569065

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387545A Abandoned CA2387545A1 (fr) 1999-10-14 2000-10-13 Methodes de traitement ou de prevention de lesions des cellules, des tissus et des organes utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1) d'origine humaine

Country Status (8)

Country Link
EP (1) EP1225911A1 (fr)
JP (1) JP2003516934A (fr)
KR (1) KR20020057976A (fr)
CN (1) CN1407900A (fr)
AU (1) AU1083401A (fr)
CA (1) CA2387545A1 (fr)
MX (1) MXPA02003801A (fr)
WO (1) WO2001026676A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20160143926A1 (en) * 2013-06-18 2016-05-26 Aminomedix Inc. Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
TWI649086B (zh) * 2015-05-22 2019-02-01 方策科技股份有限公司 用於修復軟骨缺陷的組合物
CN105267953B (zh) * 2015-09-15 2018-08-31 浙江大学 Dll4细胞因子在制备治疗暴发性肝功能衰竭药剂中的应用
CN108956967A (zh) * 2018-05-24 2018-12-07 天晴干细胞股份有限公司 一种用于细菌内毒素凝胶法检测血浆用的血浆稀释液试剂盒及其使用方法
CN111454875B (zh) * 2020-04-16 2021-12-28 中国农业科学院蔬菜花卉研究所 一种分离八仙花萼片着色细胞原生质体的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US5504003A (en) * 1994-03-08 1996-04-02 Human Genome Sciences, Inc. Macrophage inflammatory protein-3 and -4
WO1996034891A1 (fr) * 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine
KR20030097607A (ko) * 1996-09-30 2003-12-31 휴먼 게놈 사이언시즈, 인코포레이티드 골수양 선조 세포 억제 인자-1(ｍｐｉｆ-1)를 이용하여질병 상태를 치료하기 위한 치료 조성물 및 치료 방법

Also Published As

Publication number Publication date
EP1225911A1 (fr) 2002-07-31
WO2001026676A9 (fr) 2002-11-07
CN1407900A (zh) 2003-04-02
AU1083401A (en) 2001-04-23
KR20020057976A (ko) 2002-07-12
WO2001026676A1 (fr) 2001-04-19
MXPA02003801A (es) 2002-10-23
JP2003516934A (ja) 2003-05-20

Similar Documents

Publication Publication Date Title
US6495129B1 (en) Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US7402312B2 (en) Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US9403905B2 (en) Vascular endothelial growth factor 2
US6953662B2 (en) Follistatin-3
US6537966B1 (en) Follistatin-3
US7851596B2 (en) Myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptides
US20050232921A1 (en) Vascular endothelial growth factor 2
AU2002257142A1 (en) Vascular endothelial growth factor 2
JP2003523741A (ja) Ｂｃｌ−２様ポリヌクレオチド、ポリペプチドおよび抗体
KR20020092779A (ko) 혈관형성 단백질 및 이의 용도
US20030114379A1 (en) Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1)
CA2387545A1 (fr) Methodes de traitement ou de prevention de lesions des cellules, des tissus et des organes utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1) d'origine humaine
JP2003502017A (ja) ４９個のヒト分泌タンパク質
JP2003528580A (ja) ヒトニューロペプチドレセプター
JP2003501008A (ja) ５０個のヒト分泌タンパク質
JP2003500014A (ja) ５０個のヒト分泌タンパク質
JP2003515326A (ja) トランスフォーミング増殖因子αＨＩＩＩ

Legal Events

Date Code Title Description
FZDE Dead